Back to discover
Drug
Epoetin alfa
Established medicineResearchOngoing research
Also known as E.P.O., EPOETIN, ERYTHROPOIETIN, Epogen+10 more
E.P.O., EPOETIN, ERYTHROPOIETIN, Epogen, Erythropoetin, Procrit, Retacrit, epo, rhEPO, Epoetina alfa, EPOETIN ALFA,RECOMBINANT, Epoetin alfa rDNA, Epoetin alfa, recombinant, RECOMBINANT HUMAN ERYTHROPOIETIN ALFA.
RxNorm105694UNII64FS3BFH5W
1
Research papers
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this drug.
Author Correction: Erythropoietin receptor on cDC1s dictates immune tolerance
Industry2026-09-15Nature News
Research2017-02-01Kalantar-Zadeh K · American journal of nephrology
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Canonical name
Epoetin alfa
Aliases & brands
E.P.O.EPOETINERYTHROPOIETINEpogenErythropoetinProcritRetacriteporhEPOEpoetina alfaEPOETIN ALFA,RECOMBINANTEpoetin alfa rDNAEpoetin alfa, recombinantRECOMBINANT HUMAN ERYTHROPOIETIN ALFA
RxNorm CUI
105694
UNII
64FS3BFH5W
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Most influential
Journals, researchers & institutions
Top journals
- American journal of nephrology1
Leading researchers
- Kalantar-Zadeh K1
Leading institutions
free-text, unnormalised
- Harold Simmons Center for Kidney Disease Research and Epidemiology1
References & data sources
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature